After the treatment , the rate of changes of ovarian mass volume ( among them , at @ weeks after the first injection , the median was -@ % in the test group , -@ % in the control group , P = @ ) , the distinct improvement rate of symptom scores and pelvic signs during non-menstrual days -LSB- among them , at @ weeks after the first injection , the rate of lower abdomen pain was @ % ( @/@ ) in the test group , @ % ( @/@ ) in the control group , P = @ -RSB- , the hormone ( E@ , FSH , LH ) levels -LSB- among them , at @ weeks after the first injection , the serum level of E@ , was ( @ ) pmol/L in the test group , ( @ ) pmol/L in the control group , P = @ ; the serum level of FSH , was ( @ ) U/L in the test group , ( @ ) U/L in the control group , P = @ ; the serum level of LH , was ( @ ) U/L in the test group , ( @ ) U/L in the control group , P = @ -RSB- , had no statistically significant difference between the two groups ( all P > @ ) .